Secondary Hyperparathyroidism

Obtain serum calcium, phosphate, intact PTH, alkaline phosphatase, and 25-hydroxyvitamin D in CKD-associated PTH elevation; assess creatinine and BUN when distinguishing kidney-related disease from other causes of secondary hyperparathyroidism. Use trends in calcium, phosphate, PTH, and alkaline phosphatase rather than treating an individual PTH measurement as a stand-alone target. Wiley+1WileyNormocalcaemic primary hyperparathyroidism: An update on ...PubMedTreatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s

In CKD, declining phosphate excretion, impaired renal conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, and impaired calcium homeostasis drive compensatory PTH secretion. Persistent stimulation produces parathyroid hyperplasia and can progress to renal osteodystrophy, with bone pain and fracture risk. accessdata fda+1accessdata fda[PDF] 208325Orig1s000 - accessdata.fda.govPubMedSecondary Hyperparathyroidism - StatPearls - NCBI Bookshelf - NIH

When PTH is gradually rising or remains persistently elevated, specifically review phosphate concentration and dietary phosphate exposure, calcium concentration, and 25-hydroxyvitamin D status before initiating PTH-lowering medication. This sequence distinguishes a potentially reversible biochemical stimulus from severe progressive gland hyperplasia requiring targeted therapy. PubMedPubMedVitamin D: an important treatment for secondary hyperparathyroidism in chronic kidney disease? - PMC

For adults with CKD G3a-G5 not receiving dialysis, do not routinely prescribe calcitriol or vitamin D analogues solely for elevated PTH. Instead, address hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency when PTH rises progressively or remains elevated. PubMedPubMedVitamin D: an important treatment for secondary hyperparathyroidism in chronic kidney disease? - PMC

Reserve calcitriol or a vitamin D analogue for CKD G4-G5 with severe, progressive hyperparathyroidism. This restriction reflects the need to balance PTH suppression against disturbances in calcium and phosphate homeostasis and against excessive PTH suppression. PubMed+1PubMedVitamin D: an important treatment for secondary hyperparathyroidism in chronic kidney disease? - PMCPubMedVitamin D and Chronic Kidney Disease Association with Mineral and Bone Disorder: An Appraisal of Tangled Guidelines

Nutritional vitamin D repletion is appropriate for vitamin D deficiency in CKD, but defer cholecalciferol or ergocalciferol when hyperphosphatemia is uncontrolled or hypercalcemia is present. Follow calcium, phosphate, PTH, creatinine, BUN, and alkaline phosphatase as the biochemical response determines whether management remains correction-focused or requires escalation. PubMed+2PubMedHyperparathyroidism in Chronic Kidney Disease - Endotext - NCBIPubMedChronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) - NCBIPubMedCalcitriol - StatPearls - NCBI Bookshelf - NIH

For CKD G5D requiring PTH-lowering treatment, acceptable therapeutic classes are calcimimetics, calcitriol, vitamin D analogues, or combinations. Selection should be individualized to the patient’s calcium and phosphate concentrations and the direction of serial PTH, rather than by a single PTH threshold. PubMed+1PubMedVitamin D: an important treatment for secondary hyperparathyroidism in chronic kidney disease? - PMCPubMedCalcitriol - StatPearls - NCBI Bookshelf - NIH

Etelcalcetide is an intravenous calcimimetic approved for adult patients with CKD receiving hemodialysis and secondary hyperparathyroidism. In a placebo-controlled trial among dialysis patients, etelcalcetide lowered PTH more effectively than placebo. accessdata fda+1accessdata fda[PDF] 208325Orig1s000 - accessdata.fda.govJAMAEffect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in ...

Calcimimetics are a mainstay of secondary hyperparathyroidism treatment in end-stage kidney disease. If active vitamin D treatment is used, monitor calcium, phosphate, creatinine, BUN, and intact PTH; calcium requires twice-weekly monitoring during calcitriol titration. JAMA+1JAMACalcimimetic Prescriptions in Fee-for-Service Medicare ...PubMedCalcitriol - StatPearls - NCBI Bookshelf - NIH

Sustained PTH excess releases calcium and phosphate from bone and contributes to renal osteodystrophy, bone pain, and fracture risk. CKD-associated fracture risk exceeds that of age-matched controls by more than fourfold, and dialysis patients may have up to an eightfold increased risk. accessdata fda+1accessdata fda[PDF] 208325Orig1s000 - accessdata.fda.govScienceDirectMineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward

Renal osteodystrophy is a histopathologic term covering high-turnover lesions associated with secondary hyperparathyroidism, low-turnover adynamic bone disease, and osteomalacia. Because iPTH has poor diagnostic accuracy for classifying bone disease, use it as a treatment-monitoring component rather than as a definitive diagnosis of bone turnover state. Wolters Kluwer+1Wolters KluwerDiagnostic Accuracy of Biomarkers and Imaging for... - LippincottScienceDirectChronic Kidney Disease-Mineral and Bone Disorder - an overview | ScienceDirect Topics

The relevant tradeoff is not simply elevated versus normal PTH. Avoid complete PTH normalization when treating CKD-associated secondary hyperparathyroidism, particularly if serial results suggest excessive suppression or a low-turnover state. PubMed+1PubMedVitamin D and Chronic Kidney Disease Association with Mineral and Bone Disorder: An Appraisal of Tangled GuidelinesScienceDirectChronic Kidney Disease-Mineral and Bone Disorder - an overview | ScienceDirect Topics

At each treatment change, document the temporal relationship among PTH, calcium, phosphate, alkaline phosphatase, and vitamin D status. A falling PTH accompanied by worsening calcium-phosphate disturbance should prompt reassessment of the therapeutic balance rather than automatic dose escalation. PubMed+2PubMedTreatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022sPubMedVitamin D: an important treatment for secondary hyperparathyroidism in chronic kidney disease? - PMCPubMedCalcitriol - StatPearls - NCBI Bookshelf - NIH

For calcitriol, monitor serum calcium, phosphate, creatinine, BUN, and intact PTH; serum calcium should be monitored twice weekly during titration. Hypercalcemia and uncontrolled hyperphosphatemia are reasons not to proceed with nutritional vitamin D supplementation. PubMed+1PubMedChronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) - NCBIPubMedCalcitriol - StatPearls - NCBI Bookshelf - NIH

Escalate concern when PTH remains severe or progressive after correction of phosphate, calcium, dietary phosphate, and vitamin D contributors, or when the patient develops bone pain, fracture, or other CKD-MBD complications. In dialysis patients, this should trigger selection or adjustment among a calcimimetic, calcitriol, vitamin D analogue, or combination regimen. accessdata fda+3accessdata fda[PDF] 208325Orig1s000 - accessdata.fda.govPubMedVitamin D: an important treatment for secondary hyperparathyroidism in chronic kidney disease? - PMCPubMedSecondary Hyperparathyroidism - StatPearls - NCBI Bookshelf - NIHPubMedCalcitriol - StatPearls - NCBI Bookshelf - NIH